Autologous T cell therapy against CD19: Updated Phase I/II data

Updated data from 6 evaluable patients with refractory aggressive diffuse large B cell lymphoma (DLBCL) in the Phase I portion

Read the full 206 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE